N-Glycoproteomics of Patient-Derived Xenograft (PDX) Models

N-Glycoproteomics of Patient-Derived Xenograft (PDX) Models

Patient-derived xenograft (PDX) models are the future of personalized cancer therapy. Professional researchers of CD BioGlyco are dedicated to N-glycoproteomics analysis in PDX models, providing scientific help to our clients in developing tumor and cancer therapies. We look forward to being your competent research assistant in your glycoproteomics research.

Advantage of PDX models

PDX provides the most translational preclinical model for efficacy screening in cancer drug development. PDX models have the characteristic of being derived directly from patient tumors, and they can generate samples that are authentic to the host tumor. Their ability to accurately replicate tumor growth, tumor cells diversity, and tumor progression including metastatic potential reflect the heterogeneity and diversity of the human patient population.

Proteins of the cell membrane and extracellular matrix are usually N-glycosylated and can be secreted or shed into the extracellular environment. Therefore, N-glycopeptide-based enrichment can be a useful strategy for detecting tissue leakage proteins in serum. Recently, a workflow using clinically relevant PDX and N-glycopeptide enrichment was developed, which can easily identify "human-unique" proteins in mouse serum backgrounds, thus overcoming the limitations relevant to proteomics-based biomarker discovery. This strategy allowed researchers to identify potentially novel tumor-associated proteins.

A proteomics  strategy to detect tumor-associated proteins in serum of high-grade serous  ovarian carcinoma (HGSC) PDX models. Fig.1 A proteomics strategy to detect tumor-associated proteins in serum of high-grade serous ovarian carcinoma (HGSC) PDX models. (Sinha, 2019)

Our Services

CD BioGlyco has systematically developed various targeted glycoproteomics techniques such as parallel reaction monitoring mass spectrometry (PRM-MS) for the quantification of tumor-associated peptides and analysis of N-glycoproteomics in patient serum. we provide our clients with the following services but are not limited to:

  • N-glycoproteomic analysis of PDX serum and tumors.
  • Species assignment to identify tumor-associated proteins.
  • A comprehensive approach based on PDX in vitro, ex vivo, in vivo and bioinformatics data to promote drug development and speed up preclinical oncology research.


  • Identification of biomarkers to predict the tumor sensitivity of compounds
  • Development of targeted proteomic analysis for N-glycopeptides
  • Application in the development of cancer treatment

Advantages of Us

  • Years of experience in high-quality services
  • Scalable strategies - our state-of-the-art facilities are able to accept different sizes of projects
  • Complete testing from sample to result
  • Attentive after-sales service

By leveraging the wealth of information we have on multiple tumor models, CD BioGlyco has the capacity to assist clients in the N-glycoproteomics analysis of PDX models. Our professional scientific services and efficient technical support will accelerate your research related to glycoproteomics. If you need our technical assistance, please feel free to contact us and we will respond as soon as possible.


  1. Sinha, A.; et al. N-glycoproteomics of patient-derived xenografts: a strategy to discover tumor-associated proteins in high-grade serous ovarian cancer. Cell Systems. 2019, 8(4): 345-351.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.